Abstract:Gliomas, and in particular glioblastoma multiforme, are aggressive brain tumors characterized by a poor prognosis and high rates of recurrence. Current treatment strategies are based on open surgery, chemotherapy (temozolomide) and radiotherapy. However, none of these treatments, alone or in combination, are considered effective in managing this devastating disease, resulting in a median survival time of less than 15 months. The efficiency of chemotherapy is mainly compromised by the blood-brain barrier (BBB) that selectively inhibits drugs from infiltrating into the tumor mass. Cancer stem cells (CSCs), with their unique biology and their resistance to both radio- and chemotherapy, compound tumor aggressiveness and increase the chances of treatment failure. Therefore, more effective targeted therapeutic regimens are urgently required. In this article, some well-recognized biological features and biomarkers of this specific subgroup of tumor cells are profiled and new strategies and technologies in nanomedicine that explicitly target CSCs, after circumventing the BBB, are detailed. Major achievements in the development of nanotherapies, such as organic poly(propylene glycol) and poly(ethylene glycol) or inorganic (iron and gold) nanoparticles that can be conjugated to metal ions, liposomes, dendrimers and polymeric micelles, form the main scope of this summary. Moreover, novel biological strategies focused on manipulating gene expression (small interfering RNA and clustered regularly interspaced short palindromic repeats [CRISPR]/CRISPR associated protein 9 [Cas 9] technologies) for cancer therapy are also analyzed. The aim of this review is to analyze the gap between CSC biology and the development of targeted therapies. A better understanding of CSC properties could result in the development of precise nanotherapies to fulfill unmet clinical needs.

Nanobiotechnology-based treatment strategies for malignant relapsed glioma

Mechanical Nanosurgery of Chemoresistant Glioblastoma Using Magnetically Controlled Carbon Nanotubes

Nanotechnology as a new strategy for the diagnosis and treatment of gliomas

Advances in nanotechnology for the treatment of GBM

Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

Immunotherapy for Recurrent Glioma-From Bench to Bedside

Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology

Targeted Nanotechnology in Glioblastoma Multiforme

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Nanocarriers for the treatment of glioblastoma multiforme: A succinct review of conventional and repositioned drugs in the last decade

Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma

Advances in blood–brain barrier-crossing nanomedicine for anti-glioma

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms

The Nanocarrier Strategy for Crossing the Blood-Brain Barrier in Glioma Therapy

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence.